Moreover, MET, through the opioid growth factor receptor, exerts an antitumoral effect against colon cancer, neuroblastoma, ovarian cancer, head and neck squamous cell carcinoma, and pancreatic cancer [14,15,16,17]. Here, OGFR is linked to ovarian carcinoma.